vs
BillionToOne, Inc.（BLLN）与弗雷斯特研究公司（FORR）财务数据对比。点击上方公司名可切换其他公司
弗雷斯特研究公司的季度营收约是BillionToOne, Inc.的1.2倍（$101.1M vs $83.5M），BillionToOne, Inc.净利率更高（6.8% vs -33.5%，领先40.4%），BillionToOne, Inc.同比增速更快（117.4% vs -6.5%），BillionToOne, Inc.自由现金流更多（$6.5M vs $-4.3M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
BLLN vs FORR — 直观对比
营收规模更大
FORR
是对方的1.2倍
$83.5M
营收增速更快
BLLN
高出123.9%
-6.5%
净利率更高
BLLN
高出40.4%
-33.5%
自由现金流更多
BLLN
多$10.7M
$-4.3M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $101.1M |
| 净利润 | $5.7M | $-33.9M |
| 毛利率 | 69.9% | 56.7% |
| 营业利润率 | 11.5% | -36.6% |
| 净利率 | 6.8% | -33.5% |
| 营收同比 | 117.4% | -6.5% |
| 净利润同比 | 138.3% | -7941.4% |
| 每股收益（稀释后） | $0.10 | $-1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNFORR
| Q4 25 | — | $101.1M | ||
| Q3 25 | $83.5M | $94.3M | ||
| Q2 25 | — | $111.7M | ||
| Q1 25 | — | $89.9M | ||
| Q4 24 | $45.1M | $108.0M | ||
| Q3 24 | $38.4M | $102.5M | ||
| Q2 24 | — | $121.8M | ||
| Q1 24 | — | $100.1M |
净利润BLLNFORR
| Q4 25 | — | $-33.9M | ||
| Q3 25 | $5.7M | $-2.1M | ||
| Q2 25 | — | $3.9M | ||
| Q1 25 | — | $-87.3M | ||
| Q4 24 | $-11.5M | $432.0K | ||
| Q3 24 | $-14.9M | $-5.8M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $-6.7M |
毛利率BLLNFORR
| Q4 25 | — | 56.7% | ||
| Q3 25 | 69.9% | 60.0% | ||
| Q2 25 | — | 55.5% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | 57.1% | 58.8% | ||
| Q3 24 | 52.6% | 60.5% | ||
| Q2 24 | — | 57.3% | ||
| Q1 24 | — | 54.9% |
营业利润率BLLNFORR
| Q4 25 | — | -36.6% | ||
| Q3 25 | 11.5% | 4.7% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | -97.5% | ||
| Q4 24 | 17.0% | -0.5% | ||
| Q3 24 | -32.9% | -0.7% | ||
| Q2 24 | — | 9.3% | ||
| Q1 24 | — | -9.3% |
净利率BLLNFORR
| Q4 25 | — | -33.5% | ||
| Q3 25 | 6.8% | -2.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -97.1% | ||
| Q4 24 | -25.5% | 0.4% | ||
| Q3 24 | -38.8% | -5.7% | ||
| Q2 24 | — | 5.2% | ||
| Q1 24 | — | -6.7% |
每股收益（稀释后）BLLNFORR
| Q4 25 | — | $-1.75 | ||
| Q3 25 | $0.10 | $-0.11 | ||
| Q2 25 | — | $0.20 | ||
| Q1 25 | — | $-4.62 | ||
| Q4 24 | $-1.13 | $0.02 | ||
| Q3 24 | $-1.47 | $-0.30 | ||
| Q2 24 | — | $0.33 | ||
| Q1 24 | — | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $63.3M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $126.5M |
| 总资产 | $327.5M | $404.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNFORR
| Q4 25 | — | $63.3M | ||
| Q3 25 | $195.2M | $65.1M | ||
| Q2 25 | — | $67.8M | ||
| Q1 25 | — | $75.6M | ||
| Q4 24 | $191.5M | $56.1M | ||
| Q3 24 | — | $62.8M | ||
| Q2 24 | — | $58.9M | ||
| Q1 24 | — | $61.4M |
总债务BLLNFORR
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNFORR
| Q4 25 | — | $126.5M | ||
| Q3 25 | $-239.5M | $157.7M | ||
| Q2 25 | — | $159.5M | ||
| Q1 25 | — | $147.4M | ||
| Q4 24 | $-251.7M | $229.5M | ||
| Q3 24 | $-242.9M | $234.3M | ||
| Q2 24 | — | $237.1M | ||
| Q1 24 | — | $230.9M |
总资产BLLNFORR
| Q4 25 | — | $404.0M | ||
| Q3 25 | $327.5M | $414.2M | ||
| Q2 25 | — | $436.0M | ||
| Q1 25 | — | $439.8M | ||
| Q4 24 | $302.1M | $503.9M | ||
| Q3 24 | — | $505.3M | ||
| Q2 24 | — | $524.2M | ||
| Q1 24 | — | $555.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $-4.3M |
| 自由现金流率自由现金流/营收 | 7.7% | -4.2% |
| 资本支出强度资本支出/营收 | 8.8% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $18.1M |
8季度趋势，按日历期对齐
经营现金流BLLNFORR
| Q4 25 | — | $-3.2M | ||
| Q3 25 | $13.8M | $1.2M | ||
| Q2 25 | — | $-3.6M | ||
| Q1 25 | — | $26.7M | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $264.0K | ||
| Q2 24 | — | $-2.9M | ||
| Q1 24 | — | $611.0K |
自由现金流BLLNFORR
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $6.5M | $524.0K | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $26.1M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | — | $-223.0K | ||
| Q2 24 | — | $-3.7M | ||
| Q1 24 | — | $-815.0K |
自由现金流率BLLNFORR
| Q4 25 | — | -4.2% | ||
| Q3 25 | 7.7% | 0.6% | ||
| Q2 25 | — | -3.8% | ||
| Q1 25 | — | 29.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -0.2% | ||
| Q2 24 | — | -3.1% | ||
| Q1 24 | — | -0.8% |
资本支出强度BLLNFORR
| Q4 25 | — | 1.1% | ||
| Q3 25 | 8.8% | 0.7% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.4% |
现金转化率BLLNFORR
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
